Consensus statement on the management of Achondroplasia in the Middle East
Nandu Thalange, Tawfeg Ben Omran, Afaf Alsagheir, Khalid Hussain, Maha Faden, Mona Aglan, Sareea Alremeithi, Abdelhadi Habeb · 2026
Read Consensus statement on the management of Achondroplasia in the Middle East by Nandu Thalange, Tawfeg Ben Omran, Afaf Alsagheir, Khalid Hussain, Maha Faden, Mona Aglan, Sareea Alremeithi, Abdelhadi Habeb (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-13627016.txt.
Description
Nandu Thalange and seven fellow specialists write Middle East consensus guidance for achondroplasia, the most common form of skeletal dysplasia. The condition brings short stature and a lifelong list of possible nerve, breathing, bone, and social complications. A growth-promoting drug, vosoritide, recently changed what care can offer children.
Regional care lags the science: diagnosis comes late, genetic testing is patchy, and team clinics are scarce. Specialists from the region ran a modified Delphi process to settle twenty-five statements. They cover how it is found, surveillance, team care, psychosocial support, drug use, and the handover to adult care, plus research priorities for the region.
Catalog record
| CREATOR | Nandu Thalange, Tawfeg Ben Omran, Afaf Alsagheir, Khalid Hussain, Maha Faden, Mona Aglan, Sareea Alremeithi, Abdelhadi Habeb |
|---|---|
| YEAR | 2026 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 45 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |